Sangamo Therapeutics (SGMO) reported earnings on Thur 22 Feb 2018 (b/o)

 

Sangamo Therapeutics beats by $0.03, beats on revs 

• Reports Q4 (Dec) loss of $0.15 per share, $0.03 better than the Capital IQ Consensus of ($0.18); revenues rose 46.6% year/year to $13.08 mln vs the $11.1 mln Capital IQ Consensus.
• As announced separately, the co established a global collaboration and license agreement with Kite, a Gilead company, to develop next-generation cell therapies for the treatment of cancer
• As of December 31, 2017, the Company had cash, cash equivalents, marketable securities and interest receivable of $244.6 million.
• Priorities and Expectations for 2018
  • Clinical -- Demonstrate clinical progress on core assets with initial clinical data readouts by mid-year 2018
  • Pipeline -- Initiate Phase 1/2 clinical trial for ST-400 beta-thalassemia program in early 2018; support Bioverativ in filing IND application for sickle cell disease; file IND application for ST-920 Fabry disease program
  • Technology -- Continue to set gene editing standards for precision, efficiency and specificity and operationalize platform improvements
  • Partnerships -- Collaborate with the right partners to develop best-in-class medicines for patients
  • Corporate -- Establish new headquarters and construct state-of-the-art cGMP manufacturing facility in Brisbane, CA

Sangamo (SGMO): metabolic drugs given FDA fast-track status

 

Sangamo Therapeutics (SGMO) rose after the gene therapy company said the Food and Drug Administration will fast track expediting of marketing applications for two of its drugs meant to treat rare metabolic disorders.  The company said the FDA granted fast-track designations to the drugs SB-318 and SB-913, where the agency will communicate frequently with the company to help streamline the approval process. SB-318 is meant to treat Mucopolysaccharidosis Type I and SB-913 Mucopolysaccharidosis Type II, both genetic diseases where enzymes needed to break down large sugar chains in bodily tissues are not present and subsequently damage the tissue.

Sangamo Therapeutics (SGMO) reported earnings on Wed 10 May 2017 (a/h)

** charts before earnings **

** charts after earnings **

 

** the following day **

Sangamo Therapeutics beats by $0.02, misses on revs; announced strategic collaboration with Pfizer (PFE) for hemophilia a phase 1/2 gene therapy program :

• Reports Q1 (Mar) loss of $0.23 per share, $0.02 better than the Capital IQ Consensus of ($0.25); revenues fell 12.8% year/year to $3.4 mln vs the $4.14 mln Capital IQ Consensus.
• Phase 1/2 clinical trials of three lead programs are now open for enrollment In vivo genome editing treatment SB-318 for Mucopolysaccharidosis I In vivo genome editing treatment SB-913 for MPS II In vivo genome editing treatment SB-FIX for Hemophilia B Phase 1/2 clinical trial of fourth lead program, SB-525 cDNA gene therapy, for Hemophilia A to open for enrollment this quarter.
• Co announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
• Under the terms of the collaboration agreement, Sangamo will receive a $70 million upfront payment from Pfizer (PFE).Sangamo will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.
• Sangamo is eligible to receive potential milestone payments of up to $475 million, including up to $300 million for the development and commercialization of SB-525 and up to $175 million for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration.

Sangamo Therapeutics (SGMO) reported earnings on Tue 28 Feb 17 (b/o)

** charts before earnings **

 

** charts after earnings **

 

Sangamo BioSci beats by $0.11, beats on revs; guides FY17 :

• Reports Q4 (Dec) loss of $0.14 per share, $0.11 better than the Capital IQ Consensus of ($0.25); revenues fell 2.2% year/year to $8.9 mln vs the $3.9 mln Capital IQ Consensus.
• Co issues guidance for FY17, sees FY17 revs of $14-19 mln vs. $20.44 mln Capital IQ Consensus Estimate.
  • Sangamo expects that its cash, cash equivalents and marketable securities will be at least $60 million at the end of 2017, sufficient to last well beyond anticipated timing of data announcements from the four clinical trials of the Company's four lead development programs. This anticipated cash balance is inclusive of research funding from existing collaborators but exclusive of funds arising from any additional new collaborations or partnerships or other sources of capital.
• Priorities and Expectations for 2017:
  • Enroll Phase 1/2 clinical trials for Sangamo's four lead programs with data expected in late 2017 or early 2018, once the Company has gathered sufficient quantity of information from each study to understand clinical relevance:
  • Extend technological advantages (efficiency, precision, specificity) of ZFN platform for genome editing Advance novel delivery methods, including lipid nanoparticles, toward clinical development
  • Work closely with collaborator Bioverativ on the development of ZFN-mediated genome editing programs for two rare blood disorders, sickle cell disease and beta thalassemia

Sangamo Biosciences (SGMO) reported earnings Wed 3 Aug 2016 (a/h)

** charts after earnings **

 

Sangamo Biosciences posted a second quarter net loss of $26.6 million, or $0.38 per share, worse than the consensus forecast of a loss of $0.24 per share. Revenue of $3.7 million also fell well short of the estimated $5.38 million.

The California-based biopharmaceutical company expects $12 million-to-$17 million revenue for the full year. In a statement, Sangamo said that a big chunk of its quarterly revenue was generated due to agreements and research collaborations with Shire PLC (ADR) (NASDAQ:SHPG) and Biogen Idec Inc (NASDAQ:BIIB). The decrease in collaboration agreement revenue was a result of the company’s amendment to its license agreement with Shire in the third quarter of 2015, which returned the rights to Sangamo’s hemophilia treatments.